Eagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Friday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Down 1.4 %

Shares of EGRX stock opened at $4.09 on Friday. Eagle Pharmaceuticals has a 52-week low of $3.21 and a 52-week high of $19.49. The stock has a market capitalization of $53.12 million, a PE ratio of 3.47 and a beta of 0.51. The stock’s 50-day moving average price is $4.86 and its 200 day moving average price is $5.02.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of EGRX. AIGH Capital Management LLC grew its holdings in Eagle Pharmaceuticals by 2.1% during the 2nd quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock valued at $6,784,000 after buying an additional 25,000 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Eagle Pharmaceuticals during the 1st quarter worth about $83,000. Vanguard Group Inc. boosted its stake in shares of Eagle Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after purchasing an additional 2,630 shares during the last quarter. Headlands Technologies LLC grew its holdings in shares of Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 2,861 shares in the last quarter. Finally, DGS Capital Management LLC lifted its stake in shares of Eagle Pharmaceuticals by 442.5% during the first quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock valued at $325,000 after buying an additional 50,525 shares during the period. 85.36% of the stock is owned by hedge funds and other institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.